CN111566101A - Cdk4/6抑制剂及其药学上可接受的盐和多晶型物及其应用 - Google Patents

Cdk4/6抑制剂及其药学上可接受的盐和多晶型物及其应用 Download PDF

Info

Publication number
CN111566101A
CN111566101A CN201980006359.0A CN201980006359A CN111566101A CN 111566101 A CN111566101 A CN 111566101A CN 201980006359 A CN201980006359 A CN 201980006359A CN 111566101 A CN111566101 A CN 111566101A
Authority
CN
China
Prior art keywords
minus
plus
ray powder
compound
diffraction pattern
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980006359.0A
Other languages
English (en)
Other versions
CN111566101B (zh
Inventor
江涛涛
李金晶
赵双妮
姚霞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yangtze River Pharmaceutical Group Co Ltd
Shanghai Haiyan Pharmaceutical Technology Co Ltd
Original Assignee
Yangtze River Pharmaceutical Group Co Ltd
Shanghai Haiyan Pharmaceutical Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yangtze River Pharmaceutical Group Co Ltd, Shanghai Haiyan Pharmaceutical Technology Co Ltd filed Critical Yangtze River Pharmaceutical Group Co Ltd
Publication of CN111566101A publication Critical patent/CN111566101A/zh
Application granted granted Critical
Publication of CN111566101B publication Critical patent/CN111566101B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

本发明提供了一种CDK4/6抑制剂及其药学上可接受的盐和多晶型物及其应用。具体地，本发明提供了2‑环丙基‑N‑(5‑((4‑乙基哌嗪‑1‑基)甲基)吡啶‑2‑基)‑3‑异丙基‑3,8‑二氢咪唑并[4',5',4,5]环戊二烯并[1,2‑d]嘧啶‑5‑胺及其药学上可接受盐的多晶型物及其应用。此外，本发明开公开了还该化合物的药物组合物及其应用。

Description

PCT国内申请，说明书已公开。

Claims (10)

  1. PCT国内申请，权利要求书已公开。
CN201980006359.0A 2018-04-24 2019-04-23 Cdk4/6抑制剂及其药学上可接受的盐和多晶型物及其应用 Active CN111566101B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018103718322 2018-04-24
CN201810371832 2018-04-24
PCT/CN2019/083970 WO2019206154A1 (zh) 2018-04-24 2019-04-23 Cdk4/6抑制剂及其药学上可接受的盐和多晶型物及其应用

Publications (2)

Publication Number Publication Date
CN111566101A true CN111566101A (zh) 2020-08-21
CN111566101B CN111566101B (zh) 2023-08-11

Family

ID=68293743

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980006359.0A Active CN111566101B (zh) 2018-04-24 2019-04-23 Cdk4/6抑制剂及其药学上可接受的盐和多晶型物及其应用

Country Status (5)

Country Link
US (1) US20210214358A1 (zh)
EP (1) EP3786161A4 (zh)
JP (1) JP2021521282A (zh)
CN (1) CN111566101B (zh)
WO (1) WO2019206154A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023040876A1 (zh) * 2021-09-15 2023-03-23 上海海雁医药科技有限公司 氮杂芳环类化合物及其药学上可接受的盐的多晶型物、药物组合物和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101945867A (zh) * 2007-12-19 2011-01-12 安姆根有限公司 作为细胞周期抑制剂的稠合吡啶、嘧啶和三嗪化合物
JP2013532652A (ja) * 2010-07-23 2013-08-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規アミノピラゾロキナゾリン
EP3091008A1 (en) * 2013-12-31 2016-11-09 Xuanzhu Pharma Co., Ltd. Kinase inhibitor and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014183520A1 (zh) 2013-05-17 2014-11-20 上海恒瑞医药有限公司 吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用
JP2017516855A (ja) 2014-05-28 2017-06-22 シャンハイ フォチョン ファーマシューティカル カンパニー リミテッド 特定のタンパク質キナーゼ阻害剤
SG10202004716RA (en) 2014-07-24 2020-06-29 Beta Pharma Inc 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof
JP6631616B2 (ja) 2014-07-26 2020-01-15 ノース・アンド・サウス・ブラザー・ファーマシー・インベストメント・カンパニー・リミテッド ＣＤＫ阻害剤としての２−アミノ−ピリド［２，３−ｄ］ピリミジン−７（８Ｈ）−オン誘導体及びその使用
US11168088B2 (en) * 2016-11-11 2021-11-09 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Pyridylamino substituted heterotricyclic compounds, and preparation method and pharmaceutical use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101945867A (zh) * 2007-12-19 2011-01-12 安姆根有限公司 作为细胞周期抑制剂的稠合吡啶、嘧啶和三嗪化合物
JP2013532652A (ja) * 2010-07-23 2013-08-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規アミノピラゾロキナゾリン
EP3091008A1 (en) * 2013-12-31 2016-11-09 Xuanzhu Pharma Co., Ltd. Kinase inhibitor and use thereof

Also Published As

Publication number Publication date
WO2019206154A1 (zh) 2019-10-31
CN111566101B (zh) 2023-08-11
EP3786161A4 (en) 2021-05-05
EP3786161A1 (en) 2021-03-03
JP2021521282A (ja) 2021-08-26
US20210214358A1 (en) 2021-07-15

Similar Documents

Publication Publication Date Title
JP4836404B2 (ja) 抗癌化合物ｚｄ１８３９の新規結晶形
US9895377B2 (en) Solid forms of tyrosine kinase inhibitors, process for the preparation and their pharmaceutical composition thereof
US10561646B2 (en) EGFR inhibitor and pharmaceutically acceptable salt and polymorph thereof, and use thereof
CN112334469B (zh) Btk抑制剂及其药学上可接受的盐和多晶型物及其应用
CN111566101B (zh) Cdk4/6抑制剂及其药学上可接受的盐和多晶型物及其应用
CN113966332A (zh) Cdk9抑制剂的多晶型物及其制法和用途
US20230322687A1 (en) Salt of arylaminoquinazoline-containing compound, and preparation method therefor and use thereof
CN111601791B (zh) Ezh2抑制剂及其药学上可接受的盐和多晶型物及其应用
KR102270538B1 (ko) 이코티닙 포스페이트의 신규한 다형체 형태 및 이의 용도
US20220213060A1 (en) Crystal Form of Quinazolinone Compound and Preparation Method Therefor
US10544137B2 (en) PI3K inhibitor, and pharmaceutically acceptable salt, polycrystalline form, and application thereof
EP3941472A1 (en) <smallcaps/>? ? ?n? ? ? ? ?crystalline and amorphous forms of-(5-((4-ethylpiperazin-1-yl)methyl)pyridine-2-yl)-5-fluoro-4-(3-isopropyl-2-methyl-2 <ns1:i>h</ns1:i>?-indazol-5-yl)pyrimidin-2-amine and its salts, and preparation methods and therapeutic uses thereof
WO2022048551A1 (zh) 布鲁顿酪氨酸激酶抑制剂的多晶型物及其制备方法和应用
WO2023041061A1 (zh) 一种稠合二环类衍生物的可药用盐、晶型及其制备方法
CN108299419B (zh) 一种新型egfr激酶抑制剂的几种新晶型及其制备方法
KR102263410B1 (ko) 이코티닙 말레에이트의 다형체 형태 및 이의 용도
CN116836177A (zh) 一种蛋白激酶抑制剂的枸橼酸盐、其晶型、制备方法和用途
CN117794913A (zh) 嘧啶衍生物及其药学上可接受的盐的多晶型物和应用
CN117915919A (zh) 氮杂芳环类化合物及其药学上可接受的盐的多晶型物、药物组合物和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant